Generic Xipere Availability
Last updated on Aug 7, 2024.
Xipere is a brand name of triamcinolone ophthalmic, approved by the FDA in the following formulation(s):
XIPERE (triamcinolone acetonide - suspension;injection)
-
Manufacturer: BAUSCH AND LOMB INC
Approval date: October 22, 2021
Strength(s): 40MG/ML [RLD]
Has a generic version of Xipere been approved?
No. There is currently no therapeutically equivalent version of Xipere available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xipere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods and devices for drug delivery to ocular tissue using microneedle
Patent 8,636,713
Issued: January 28, 2014
Inventor(s): Prausnitz Mark R. & Edelhauser Henry F. & Patel Samirkumar RajnikantMethods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
Patent expiration dates:
- May 2, 2027✓
- May 2, 2027
-
Methods and devices for the treatment of ocular diseases in human subjects
Patent 9,636,332
Issued: May 2, 2017
Inventor(s): Zarnitsyn Vladimir & Patel Samirkumar & White Daniel & Noronha Glenn & Burke Brian
Assignee(s): CLEARSIDE BIOMEDICAL, INC.Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
Patent expiration dates:
- November 8, 2033✓
- November 8, 2033
-
Apparatus and methods for ocular injection
Patent 9,937,075
Issued: April 10, 2018
Inventor(s): Andino Rafael Victor & Zarnitsyn Vladimir & Yoo Jesse & Brooks Christopher John & Kahute Trent John & Arsenault Justin William & Trettin David Jackson & Bauer Andrew Kent & Lewis Stephanie Elaine
Assignee(s): CLEARSIDE BIOMEDICAL, INC.An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.
Patent expiration dates:
- May 2, 2034✓
- May 2, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 22, 2024 - NEW PRODUCT
More about Xipere (triamcinolone ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic steroids
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
